Tumorantigene und ihre Nutzung für eine Therapie mit Antikörpern

  • Burkhard Micheel
Part of the Handbuch der Molekularen Medizin book series (HDBMOLEK, volume 2)


Das Konzept einer immunologischen Therapie von Tumoren basiert auf der Ende des vergangenen Jahrhunderts entwickelten Vorstellung, daß Krebszellen ebenso wie die Erreger einer Infektionserkrankung vom Immunsystem der Wirbeltiere als fremd erkannt und zerstört werden können. Bei Tumorpatienten müßte demzufolge durch geeignete Maßnahmen eine Stimulierung des Immunsystems möglich sein, die letztendlich zur Heilung einer Krebserkrankung führt [Old 1992, 1996]. Voraussetzungen für eine Immunreaktion gegen Tumoren sind:
  • Vorhandensein von molekularen Strukturen auf bzw. in den Tumorzellen, die sie von Normalzellen unterscheiden und.

  • Erkennung dieser Strukturen als „fremd“ durch Komponenten des Immunsystems.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abelev GI (1968) Production of embryonal serum alpha globulin by hepatomas. Review of experimental and clinical data. Cancer Res 28: 1344–1350PubMedGoogle Scholar
  2. Bagshawe KD, Sharma SK, Springer CJ et al. (1994) Antibody directed enzyme prodrug therapy (ADEPT): review. Ann Oncol 5: 879–891PubMedGoogle Scholar
  3. Barnd DL, Lan M, Metzger RS et al. (1991) Specific, MHC-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86: 7159–7163CrossRefGoogle Scholar
  4. Becker JC, Brabletz T, Czerny C et al. (1993) Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class 11+ melanoma. Int Immunol 5: 1501–1508PubMedCrossRefGoogle Scholar
  5. Begent RH, Verhaar MJ, Chester KA et al. (1996) Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 2: 979–984PubMedCrossRefGoogle Scholar
  6. Berenson RJ, Bensinger WI, Hill RS et al. (1991) Engraftment after infusion of CD34+ marrow cells in patients with breast cancer and neuroblastoma. Blood 77: 1717–1722PubMedGoogle Scholar
  7. Billetta R, Luglio AF (1993) Chimeric antibodies. Int Rev Immunol 10: 165–176PubMedCrossRefGoogle Scholar
  8. Bishop M (1991) Molecular themes in oncogenesis. Cell 64: 235–248PubMedCrossRefGoogle Scholar
  9. Bocchia M, Korontsevit T, Xu Q et al. (1996) Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87: 3587–3592PubMedGoogle Scholar
  10. Boon T (1993) Teaching the immune system to fight cancer. Scientific Am 266: 32–39CrossRefGoogle Scholar
  11. Boon T, Bruggen P van der (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183: 725–729PubMedCrossRefGoogle Scholar
  12. Boon T, Cerottini JC, Van den Eynde B et al. (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337–365PubMedCrossRefGoogle Scholar
  13. Bottger V, Micheel B, Scharte G et al. (1993) Monoclonal antibodies to human chorionic gonadotropin (HCG) and their use in two-site binding enzyme immunoassays. Hybridoma 12: 81–91PubMedCrossRefGoogle Scholar
  14. Brown SL, Miller RA, Horning SJ et al. (1989) Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73: 651–661PubMedGoogle Scholar
  15. Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13: 1–27PubMedGoogle Scholar
  16. Burrows FJ, Thorpe PE (1993) Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 90: 8996–9600PubMedCrossRefGoogle Scholar
  17. Canevari S, Pupa SM, Menard S (1996) 1975–1995 revised anti-cancer serological response: biological significance and clinical implications. Ann Oncol 7: 227–232PubMedGoogle Scholar
  18. Canon JL, Humblet Y, Lebacq-Verheyden AM et al. (1988) Immunodetection of small cell lung cancer metastases in bone marrow using three monoclonal antibodies. Eur J Cancer 24: 147–150CrossRefGoogle Scholar
  19. Caron PC, Scheinberg DA (1993) Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia. Leuk Lymphoma [Suppl 2] 11: 1–6PubMedCrossRefGoogle Scholar
  20. Caron PC, Scheinberg DA (1994) Immunotherapy for acute leukemias. Curr Opin Oncol 6: 14–22PubMedCrossRefGoogle Scholar
  21. Carubia JM, Yu RK, Macaela LJ et al. (1984) Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun 120: 500–504PubMedCrossRefGoogle Scholar
  22. Chapman PB (1995) Anti-idiotypic monoclonal antibody cancer vaccines. Semin Cancer Biol 6: 367–374PubMedCrossRefGoogle Scholar
  23. Cheever MA, Disis ML, Bernard H et al. (1995) Immunity to oncogenic proteins. Immunol Rev 145: 33–59PubMedCrossRefGoogle Scholar
  24. Chen W, Peace DJ, Rovira DK et al. (1992) T-cell immunity to the joining region of p210 bcr-abl protein. Proc Natl Acad Sci USA 89: 1468–1472PubMedCrossRefGoogle Scholar
  25. Chen YT, Stockert E, Chen Yet al. (1994a) Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci USA 91: 1004–1008PubMedCrossRefGoogle Scholar
  26. Chen TT, Tao MH, Levy R (1994b) Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 153: 4775–4787PubMedGoogle Scholar
  27. Chetanneau A, Baum RB, Lehur PA et al. (1990) Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19–9 monoclonal antibody F(ab)2 fragments. Eur J Nucl Med 17: 223–229PubMedCrossRefGoogle Scholar
  28. Colnaghi MI, Menard S, Canevari S (1993) Evolution of the therapeutic use of new monoclonal antibodies. Curr Opin Oncol 5: 1035–1042PubMedCrossRefGoogle Scholar
  29. Coulie PG, Brichard V, Van Pel A et al. (1995) A mutate intron sequence codes for an epitope of an anigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92: 7976–7980PubMedCrossRefGoogle Scholar
  30. De Campos-Lima PO, Gavioli R, Zhang Q-J et al. (1993) HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science 260: 179–181Google Scholar
  31. Di Fiore PP, Heiin K, Kraus MH et al. (1992) A single amino acid substitution is sufficient to modify the mitogenic properties of the epidermal growth factor receptor to resemble that of gp185er-2. EMBO J 11: 3927–3933PubMedGoogle Scholar
  32. Dillman RO (1994) Antibodies as cytotoxic therapy. J Clin Oncol 12: 1497–1515PubMedGoogle Scholar
  33. Disis ML, Cheever MA (1996) Oncogenic proteins as tumor-antigens. Curr Opin Immunol 8: 637–642PubMedCrossRefGoogle Scholar
  34. Dyer MJ, Hale G, Hayhoe FG et al. (1989) Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73: 1431–1439PubMedGoogle Scholar
  35. Elias DJ, Hirschowitz L, Kline LE et al. (1990) Phase I clinical comparative study of monoclonal antibody KS 1/4 and KSl/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res 50: 4154–4159PubMedGoogle Scholar
  36. Epstein AL, Khawli LA (1991) Tumor biology and monoclonal antibodies: overview of principles and clinical considerations. Antibody Immunoconjug Radiopharm 4: 373–384Google Scholar
  37. Featherstone C (1996) Bispecific antibodies: the new magic bullets. Lancet 348: 536PubMedCrossRefGoogle Scholar
  38. Ferrone S (1990) Monoclonal antibodies and tumor vaccines. Curr Opin Oncol 2: 1146–1151PubMedCrossRefGoogle Scholar
  39. Fidler IJ (1990) Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes memorial award lecture. Cancer Res 50: 6130–6138PubMedGoogle Scholar
  40. Fiebig HH (1995) Durchführung von klinischen Studien. In: Zeller WJ, Zur Hausen H (Hrsg) Onkologie, Grundlagen, Diagnostik, Therapie, Entwicklungen, ecomed, Landsberg/Lech, IV-2, S 1–5Google Scholar
  41. Finn OJ (1993) Tumor-rejection antigens recognized by T lymphocytes. Curr Opin Immunol 5: 701–708PubMedCrossRefGoogle Scholar
  42. Finn OJ, Jerome K, Henderson RA et al. (1995) MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145: 61–89PubMedCrossRefGoogle Scholar
  43. Foley EJ (1953) Antigenic properties of methylcholanthrene-induced tumors in mice in the strain of origin. Cancer Res 13: 835–837PubMedGoogle Scholar
  44. Garin-Chesa P, Old LJ, Rettig WJ (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 87: 7235–7239PubMedCrossRefGoogle Scholar
  45. Gendler S, Lancaster C, Taylor-Papadimitriou J et al. (1990) Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265: 15286PubMedGoogle Scholar
  46. Girling A, Bartkova J, Burchell J et al. (1989) A core protein of the polymorphic epithelial mucin detected by the monoclonal antibody SM3 is selectively exposed in a range of primary carcinomas. Int J Cancer 43: 1072–1075PubMedCrossRefGoogle Scholar
  47. Gold P, Freeman SO (1965) Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and adsorption techniques. J Exp Med 121: 439–445PubMedCrossRefGoogle Scholar
  48. Goodman GE, Hellström I, Yelton DE et al. (1993) Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 36: 267–273PubMedCrossRefGoogle Scholar
  49. Göttlinger HG, Funke I, Johnson JP et al. (1986) The epithelial cell surface antigen 17–1 A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 38: 47–53PubMedCrossRefGoogle Scholar
  50. Grossbord ML, Press OW, Applebaum FR et al. (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80: 863–878Google Scholar
  51. Hakamori S (1985) Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 52: 257–331CrossRefGoogle Scholar
  52. Hellström KE, Hellström I (1969) Cellular immunity against tumor specific antigens. Adv Cancer Res 12: 167–223PubMedCrossRefGoogle Scholar
  53. Henderson RA, Finn OJ (1996) Human tumor antigens are ready to fly. Adv Immunol 62: 217–256PubMedCrossRefGoogle Scholar
  54. Herlyn D, Wettendorff M, Koprowski H (1989) Modulation of cancer patients’ immune responses by anti-idiotypic antibodies. Int Rev Immunol 4: 347–357PubMedCrossRefGoogle Scholar
  55. Hollstein M, Sidransky D, Vogelstein B et al. (1991) P53 mutations in human cancer. Science 253: 49–53PubMedCrossRefGoogle Scholar
  56. Houbiers JGA, Van der Burg SH, Van de Watering LMG et al. (1995) Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 72: 673–641CrossRefGoogle Scholar
  57. Houghton AN, Larson S (1989) Monoclonal antibodies for the treatment of cancer: therapeutic strategies. Curr Opin Oncol 1: 258–265PubMedGoogle Scholar
  58. Huston JS, Martney J, Tai MS et al. (1993) Medical applications of single-chain antibodies. Int Rev Immunol 10: 195–217PubMedCrossRefGoogle Scholar
  59. Hwu P, Yang JC, Cowherd R et al. (1995) In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55: 3369–3373PubMedGoogle Scholar
  60. Jacobs AJ, Fer M, Su FM et al. (1993) A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol 82: 586–593PubMedCrossRefGoogle Scholar
  61. Janson CH, Tehrani M, Wigzell H et al. (1989) Rational use of biological response modifiers in hematological malignancies – a review of treatment with interferon, cytotoxic cells and antibodies. Leuk Res 13: 1039–1046PubMedCrossRefGoogle Scholar
  62. Jantscheff P, Böttger V, Price M et al. (1991) Production and characterization of monoclonal antibodies against carcinoembryonic antigen (CEA). Biomed Biochim Acta 50: 1261–1267PubMedGoogle Scholar
  63. Jurcic JG, Scheinberg DA (1994) Recent developments in the radioimmunotherapy of cancer. Curr Opin Immunol 6: 715–721PubMedCrossRefGoogle Scholar
  64. Jurcic JG, Caron PC, Scheinberg DA (1995) Monoclonal antibody therapy of leukemia and lymphoma. Adv Pharmacol 33: 287–314PubMedCrossRefGoogle Scholar
  65. Kaminski MS, Zasadny KR, Francis IR et al. (1993) Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329: 459–465PubMedCrossRefGoogle Scholar
  66. Kaminski MS, Zasadny KR, Francis IR et al. (1996) Iodine-131-anti-Bl radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14: 1974–1981PubMedGoogle Scholar
  67. Kane M (1995) Global programme for control of hepatitis B infection. Vaccine [Suppl 1] 13: 47–49Google Scholar
  68. Karawajew L, Micheel B, Behrsing O et al. (1987) Bispecific antibody-producing hybrid hybridomas selected by a fluorescence activated cell sorter. J Immunol Methods 96: 265–270PubMedCrossRefGoogle Scholar
  69. Kasprzyk PG, Song SU, Di Fiore PP et al. (1992) Therapy of an animal model of human gastric cancer using a combination of anti-er-2 monoclonal antibodies. Cancer Res 52: 2771–2776PubMedGoogle Scholar
  70. Klein G, Boon T (1993) Cancer. Tumor immunology: present perspectives. Curr Opin Immunol 5: 687–692PubMedCrossRefGoogle Scholar
  71. Klein G, Klein E (1964) Antigenic properties of lymphomas induced by the Moloney agent. J Natl Cancer Inst 32: 547–568PubMedGoogle Scholar
  72. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497PubMedCrossRefGoogle Scholar
  73. Kotera Y, Fontenot JD, Pecher G et al. (1994) Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res 54: 2856–2860PubMedGoogle Scholar
  74. Kuriyama M, Wang MC, Lee CI et al. (1981) Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41: 3874–3876PubMedGoogle Scholar
  75. Kuzel TM, Rosen ST (1994) Antibodies in the treatment of human cancer. Curr Opin Oncol 6: 622–626PubMedCrossRefGoogle Scholar
  76. Lanzavecchia A (1995) How can cryptic epitopes trigger autoimmunity? J Exp Med 181: 1945–1948PubMedCrossRefGoogle Scholar
  77. Levy R, Miller RA (1990) Therapy of lymphoma directed at idiotypes. Monogr Natl Cancer Inst 10: 61–68PubMedGoogle Scholar
  78. Li LC, Zhang YS, Lin Q et al. (1995) Clinical application of monoclonal antibody drug conjugate to immunotargeting chemotherapy of bladder cancer. Chin Med J (Engl) 108: 764–768Google Scholar
  79. Linehan DC, Goedegebuure PS, Eberlein TJ (1996) Vaccine therapy for cancer. Ann Surg Oncol 3: 219–228PubMedCrossRefGoogle Scholar
  80. Livingston PO (1995) Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccine. Immunol Rev 145: 147–166PubMedCrossRefGoogle Scholar
  81. Lloyd KO (1987) Blood group antigens as markers for normal cell differentiation and malignant change in human tissues. Am J Clin Pathol 87: 129–139PubMedGoogle Scholar
  82. Lloyd KO (1991) Humoral immune responses to tumor-associated carbohydrate antigens. Cancer Biol 2: 421–431Google Scholar
  83. Lloyd KO, Old LJ (1989) Human monoclonal antibodies to glycolipids and other carbohydrate antigens: dissection of the humoral immune response in cancer patients. Cancer Res 49: 3445–3451PubMedGoogle Scholar
  84. LoBuglio AF, Saleh MN (1992a) Monoclonal antibody therapy of cancer. Crit Rev Oncol Hematol 13: 271–282PubMedCrossRefGoogle Scholar
  85. LoBuglio AF, Saleh MN (1992b) Advances in monoclonal antibody therapy of cancer. Am J Med Sci 304: 214–224PubMedCrossRefGoogle Scholar
  86. Luiten RM, Coney LR, Fleuren GJ et al. (1996) Generation of chimeric bispecific G250/anti CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br J Cancer 74: 735–744PubMedCrossRefGoogle Scholar
  87. Mack M, Riethmuller G, Kufer P (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92: 7021–7025PubMedCrossRefGoogle Scholar
  88. Mansi JL, Easton D, Berger U et al. (1991) Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years’ follow-up. Eur J Cancer 27: 1552–1555PubMedCrossRefGoogle Scholar
  89. Marks C, Marks JD (1996) Phage libraries – a new route to clinically useful antibodies. N Engl J Med 335: 730–733PubMedCrossRefGoogle Scholar
  90. Masucci MA (1993) Viral immunopathology of human tumors. Curr Opin Immunol 5: 693–700PubMedCrossRefGoogle Scholar
  91. Masucci G, Ragnhammar P, Wersall P et al. (1990) Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (b 17–1 A). Cancer Immunol Immunother 31: 231–235PubMedCrossRefGoogle Scholar
  92. Mattes MJ, Thomson TM, Old LJ et al. (1983) A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int J Cancer 32: 717–721PubMedCrossRefGoogle Scholar
  93. Matthews DC, Smith FO, Bernstein ID (1992) Monoclonal antibodies in the study and therapy of hematopoietic cancers. Curr Opin Immunol 4: 641–646PubMedCrossRefGoogle Scholar
  94. Melief CJM, Offringa R, Toes REM et al. (1996) Peptide-based cancer vaccines. Curr Opin Immunol 8: 651–657PubMedCrossRefGoogle Scholar
  95. Mellstedt H (1990) Monoclonal antibodies in cancer therapy. Curr Opin Immunol 2: 708–713CrossRefGoogle Scholar
  96. Mellstedt H, Frodin JE, Ragnhammar P et al. (1989) The clinical use of monoclonal antibodies, MAb 17–1 A, in the treatment of patients with metastatic colorectal carcinoma. Med Oncol Tumor Pharmacother 6: 99–107PubMedGoogle Scholar
  97. Miller RA, Maloney DG, Warnke R et al. (1982) Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 30: 517–522CrossRefGoogle Scholar
  98. Mittelman A, Chen ZJ, Yang H et al. (1992) Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2–23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89: 466–470PubMedCrossRefGoogle Scholar
  99. Modjtahedi H, Hickish T, Nicolson M et al. (1996) Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 73: 228–235PubMedCrossRefGoogle Scholar
  100. Natali PG, Siccardi AG (1990) Monoclonal antibodies in cancer diagnosis. Curr Opin Immunol 2: 697–701CrossRefGoogle Scholar
  101. Nimgaonkar M, Kemp A, Lancia J et al. (1996) A combination of CD34 selection and complement-mediated immunopurging (anti-CD 15 monoclonal antibody) eliminates tumor cells while sparing normal progenitor cells. J Hematother 5: 39–48PubMedCrossRefGoogle Scholar
  102. O’Boyle KP, Zamore R, Adluri S et al. (1992) Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces I and I antibodies to sialylated Tn. Cancer Res 52: 5663–5667PubMedGoogle Scholar
  103. Oettgen HF, Rettig WJ, Lloyd KO et al. (1990) Serologic analysis of human cancer. Immunol Allergy Clin North Am 10: 607–637Google Scholar
  104. Old LJ (1981) Cancer immunology: the search for specificity. Cancer Res 41: 361–375PubMedGoogle Scholar
  105. Old LJ (1992) Cancer. Tumor immunology: the first century. Curr Opin Immunol 4: 603–607PubMedCrossRefGoogle Scholar
  106. Old LJ (1996) Immuntherapy of cancer. Scientific Am 275: 102–109CrossRefGoogle Scholar
  107. Pantel K, Riethmuller G (1996) Micrometastasis detection and treatment with monoclonal antibodies. Curr Top Microbiol Immunol 213: 1–18PubMedGoogle Scholar
  108. Pantel K, Schlimok G, Kutter D et al. (1991) Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 51: 4712–4715PubMedGoogle Scholar
  109. Pardoll DM (1996) Cancer vaccines: a road map for the next decade. Curr Opin Immunol 8: 619–621PubMedCrossRefGoogle Scholar
  110. Parham P (1996) Pictures of MHC restriction. Nature 384: 109–110PubMedCrossRefGoogle Scholar
  111. Pasternak G, Graffi A, Horn K-H (1964) Der Nachweis individualspezifischer Antigenität bei UV-induzierten Sarkomen der Maus. Acta Biol Med Ger 13: 276–279PubMedGoogle Scholar
  112. Peyrat J-P, Bonneterre J, Lubin R et al. (1995) Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 345: 621–622PubMedCrossRefGoogle Scholar
  113. Prehn RT, Main JM (1957) Immunity of methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18: 769–778PubMedGoogle Scholar
  114. Reid HA (1975) Antivenom in sea-snake bit poisoning. Lancet I: 622–623Google Scholar
  115. Renner C, Pfreundschuh M (1995) Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev 145: 179–209PubMedCrossRefGoogle Scholar
  116. Rensing-Ehl A, Frei K, Flury R et al. (1995) Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 25: 2253–2258PubMedCrossRefGoogle Scholar
  117. Restifo NP, Esquivel F, Kawakami Y (1993) Identification of human cancers deficient in antigen processing. J Exp Med 177: 265–272PubMedCrossRefGoogle Scholar
  118. Rettig WJ (1992) Immunogenetics of cell surface antigens of human cancer. Curr Opin Immunol 4: 630–640PubMedCrossRefGoogle Scholar
  119. Rettig WJ, Garin-Chesa P, Healey H et al. (1992) Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89: 10832–10836PubMedCrossRefGoogle Scholar
  120. Rickinson AB (1995) Immune intervention against virus-associated human cancers. Ann Oncol [Suppl 1] 6: 69–71PubMedGoogle Scholar
  121. Riethmüller G, Johnson JP (1992) Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. Curr Opin Immunol 4: 647–655PubMedCrossRefGoogle Scholar
  122. Riethmüller G, Schneider-Gädicke E, Johnson JP (1993) Monoclonal antibodies in cancer therapy. Curr Opin Immunol 5: 732–739PubMedCrossRefGoogle Scholar
  123. Riethmüller G, Schneider-Gädicke E, Schlimok G et al. (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German cancer aid 17–1A study group. Lancet 343: 1177–1183PubMedCrossRefGoogle Scholar
  124. Roth C, Rochlitz C, Kourilsky P (1994) Immune response against tumors. Adv Immunol 57: 281–351PubMedCrossRefGoogle Scholar
  125. Rughetti A, Turchi V, Ghetti CA et al. (1993) Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 53: 2457–2459PubMedGoogle Scholar
  126. Sahin U, Türeci Ö, Schmitt H et al. (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92: 11810–11813PubMedCrossRefGoogle Scholar
  127. Scheinberg DA, Tanimoto M, Menzie S et al. (1989) Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia 3: 440–445PubMedGoogle Scholar
  128. Scheper RJ, Bülte JW, Brakkee JG et al. (1988) Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer 42: 389–394PubMedCrossRefGoogle Scholar
  129. Schlichtholz B, Legros Y, Gillet D et al. (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spots. Cancer Res 52: 6380–6384PubMedGoogle Scholar
  130. Schlimok G, Funke I, Holzmann B et al. (1987) Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17–1A monoclonal antibodies. Proc Natl Acad Sci USA 84: 8672–8676PubMedCrossRefGoogle Scholar
  131. Schneider-Gädicke E, Riethmüller G (1995) Prevention of manifest metastasis with monoclonal antibodies: a novel approach to immunotherapy of solid tumours. Eur J Cancer 31A: 1326–1330PubMedCrossRefGoogle Scholar
  132. Sercarz EE, Lehmann PV, Amentani A et al. (1993) Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11: 729–766PubMedCrossRefGoogle Scholar
  133. Shively J, Beatty J (1985) CEA related antigens: molecular, biological and clinical significance. Crit Rev Oncol Hematol 2: 355–399PubMedCrossRefGoogle Scholar
  134. Steffens TA, Bajorin DF, Houghton AN (1992) Immuntherapy with monoclonal antibodies in metastatic melanoma. World J Surg 16: 261–269PubMedCrossRefGoogle Scholar
  135. Streit M, Schmidt R, Hilgenfeld RU et al. (1996) Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. J Mol Med 74: 253–268PubMedCrossRefGoogle Scholar
  136. Sugawa N, Ekstrand AJ, James CD et al. (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastoma. Proc Natl Acad Sci USA 87: 8602–8606PubMedCrossRefGoogle Scholar
  137. Suresh MR (1996) Classification of tumor markers. Anticancer Res 16: 2273–2278PubMedGoogle Scholar
  138. Thanavala Y (1996) Novel approaches to vaccine development against HBV. J Biotechnol 44: 67–73PubMedCrossRefGoogle Scholar
  139. Thomson J, Grunert F, Zimmermann W (1991) CEA gene family: molecular biology and clinical perspective. J Clin Lab Anal 5: 344–366CrossRefGoogle Scholar
  140. Thrush GR, Lark LR, Clinchy BC et al. (1996) Immunotoxins. An update. Annu Rev Immunol 14: 49–71PubMedCrossRefGoogle Scholar
  141. Tindle RW (1996) Human vaccines for cervical cancer. Curr Opin Immunol 8: 643–650PubMedCrossRefGoogle Scholar
  142. Tsang KY, Zaremba S, Nieroda CA et al. (1995) Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87: 982–990PubMedCrossRefGoogle Scholar
  143. Tyer L, Vredenburgh JJ, Heimer M et al. (1996) Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique. Clin Cancer Res 2: 81–86PubMedGoogle Scholar
  144. Urban JL, Schreiber H (1992) Tumor antigens. Annu Rev Immunol 10: 617–644PubMedCrossRefGoogle Scholar
  145. Van der Brüggen P (1994) The long-standing quest for tumor rejection antigens. Clin Immunol Immunopathol 71: 248–252PubMedCrossRefGoogle Scholar
  146. Van der Brüggen P, Van den Eynde B (1992) Molecular definition of tumor antigens recognized by T lymphocytes. Curr Opin Immunol 4: 608–612PubMedCrossRefGoogle Scholar
  147. Vieira P, Waal-Malefyt RD, Dang M-N et al. (1991) Isolation and expression of human cytokine synthesis inhibitory factor NA clones; homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 88: 1172–1176PubMedCrossRefGoogle Scholar
  148. Vijayasyradhi S, Bouchard BB, Houghton AN (1990) The melanoma antigen gp75 is the human homologue to mouse b (BROWN) locus gene. J Exp Med 171: 1375–1380CrossRefGoogle Scholar
  149. Vitetta ES, Thorpe PE, Uhr JW (1993) Immunotoxins: magic bullits or misguided missiles? Immunol Today 14: 252–259PubMedCrossRefGoogle Scholar
  150. Waldmann TA (1996) The promiscuous IL 2/IL 15 receptor: a target for immunotherapy of HTLV I associated disorders. J Acquir Immune Defic Syndr Hum Retrovirol [Suppl] 13: 179–185CrossRefGoogle Scholar
  151. Waldmann TA, Goldman CK, Bongiovanni KF et al. (1988) Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 72: 1805–1816PubMedGoogle Scholar
  152. Wang RF, Parkhurst MR, Kawakami Y et al. (1996) Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 183: 1131–1140PubMedCrossRefGoogle Scholar
  153. Weiner M, Clark JI, Davey M et al. (1995) Phase I trial of 2B1, a bispecific monoclonal antibody targeting c er-2 and Fc gamma RIII. Cancer Res 55: 4586–4593PubMedGoogle Scholar
  154. Welt S, Divgi CR, Real FX et al. (1990) Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol 8: 1894–1906PubMedGoogle Scholar
  155. Welt S, Divgi CR, Scott AM et al. (1994) Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol 12: 1193–1203PubMedGoogle Scholar
  156. Welt S, Divgi CR, Kemeny NE et al. (1996) Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 14: 1787–1797PubMedGoogle Scholar
  157. Wettendorff M, Iliopoulos D, Tempero M et al. (1989) Idiotypic cascades in cancer patients treated with monoclonal antibody C017–1A. Proc Natl Acad Sci USA 86: 3787–3791PubMedCrossRefGoogle Scholar
  158. Winter G, Harris WJ (1993) Humanized antibodies. Immunol Today 14: 243–246PubMedCrossRefGoogle Scholar
  159. Yefenof E, Picker LJ, Scheuermann RH et al. (1993) Induction of B cell tumor dormancy by anti-idiotypic antibodies. Curr Opin Immunol 5: 740–744PubMedCrossRefGoogle Scholar
  160. Zotter S, Hagemann PC, Lossnitzer A et al. (1988) Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 11: 55–101Google Scholar
  161. Zur Hausen H, Villiers EM de (1994) Human papillomaviruses. Annu Rev Microbiol 48: 427–447PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Burkhard Micheel

There are no affiliations available

Personalised recommendations